Literature DB >> 6482877

In vitro studies on the distribution of probucol among human plasma lipoproteins.

S Urien, P Riant, E Albengres, R Brioude, J P Tillement.   

Abstract

The role of human plasma lipoproteins as carriers in the blood transport of the cholesterol-lowering and water-insoluble drug, probucol, was investigated in in vitro studies. [14C]Probucol was incubated in whole human blood, a serum pool, individual diluted sera, and isolated protein and lipoprotein fractions. In whole blood, about 90% partitioned in plasma. Following ultracentrifugal fractionation of the serum, it was found that less than 5% distributed in the d greater than 1.20 protein fraction (albumin-rich fraction) and more than 95% in the lipoprotein fractions. The distribution of probucol in the lipoprotein fractions correlated with the lipoprotein total lipid volume under saturation conditions (incubation of isolated lipoprotein fractions) as well as nonsaturation conditions (fractionation of serum exposed to [14C]probucol). Incubation of the albumin-rich fraction and of apolipoproteins originating from the isolated lipoprotein fractions showed that they account for a negligible part in the interaction of probucol with blood components. The probucol uptake of individual sera was shown to be correlated to the lipid content of the serum. When probucol was incubated in erythrocyte suspensions containing variable amounts of lipoproteins, probucol partitioned less in erythrocytes as the lipoprotein concentration increased in the suspension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482877

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol.

Authors:  T Komura; K Takahara; M Sugano; A Fujinishi; H Tasaki; Y Nakashima; A Kuroiwa
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.441

2.  Positive correlation between probucol in low density lipoprotein and LDL-lowering.

Authors:  M Shinomiya; K Shirai; Y Saito; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative.

Authors:  S Parthasarathy
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs.

Authors:  K Hosoe; T Mae; E Konishi; K Fujii; K Yamashita; T Yamane; T Hidaka; T Ohashi
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 5.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

Review 6.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

7.  Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.

Authors:  T J Neale; P P Ojha; M Exner; H Poczewski; B Rüger; J L Witztum; P Davis; D Kerjaschki
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.